The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas
More details
Hide details
Department of Nuclear Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey
Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey
Department of Statistics, Faculty of Medicine, Trakya University, Edirne, Turkey
Department of Medical Oncology, Acıbadem Eskişehir Hospital, Eskişehir, Turkey
Department of Radiation Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey
Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkey
Submission date: 2019-05-21
Final revision date: 2020-04-20
Acceptance date: 2020-04-20
Publication date: 2020-05-15
Pol J Radiol, 2020; 85: 254-260
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) combined with computed tomo­graphy (CT) scan is accepted as a standard tool in the staging of oesophageal cancer (OC). Histological subtype of tumour is known to be a major determinant of prognosis and metabolic behaviour. In this study, we aimed to evaluate the effect of histological subtypes of OC on standard uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) obtained by PET/CT, and also to compare this effect with prognosis.

Material and methods:
Images and clinical course data of 57 patients who were diagnosed with EC and treated in our hospital between 2009 and 2016 were evaluated in a retrospective manner. PET/CT images were re-analysed in terms of metabolic parameters, and observations were compared with histological subtypes.

No significant difference was observed between histological subtypes with SUVmax, overall survival (OS), or progression-free survival (PFS). Thus, MTV was observed to be related with histological subtype; MTV values of adenocancer patients were significantly higher than those of squamous cell cancer patients.

Metabolic tumour volume was related with histological subtype of OC, but clinical staging, TLG, and SUVmax values were not related with histological subtype, which may suggest the use of MTV as a routine parameter for OC and inclusion of MTV observations in prognostic scoring.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 2018; 68: 394-424.
Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015; 64: 381-387.
Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
Harada K, Kaya DM, Lopez A, et al. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med 2018; 6: 80.
Zhang P, Li Z, Wang D, et al. 18F fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy. Oncol Lett 2018; 15: 1845-1852.
Van De Wiele C, Kruse V, Smeets P, et al. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 2013; 40: 290-301.
Usmanij EA, De Geus-Oei LF, Troost EGC, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated withconcomitant chemoradiotherapy. J Nucl Med 2013; 54: 1528-1534.
Sahiner I, Atasever T, Akdemir UO, et al. Relationship between primary lesion metabolic parameters and clinical stagein lung cancer. Rev Esp Med Nucl Imagen Mol 2013; 32: 357-363.
Ho Seok I, Kim SJ, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med 2012; 37: 442-446.
Fan B, Fan P, Kong L, et al. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. Oncotarget 2017; 8: 34498-34506.
Kim SJ, Pak K, Chang S. Determination of regional lymph node status using 18F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity. Br J Radiol 2016; 89: 20150673.
Yildirim BA, Torun N, Guler OC, Onal C. Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy. Nucl Med Commun 2018; 39: 553-563.
Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010; 17: 115-122.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1: 122S-150S.
Soydal C, Yüksel C, Küçük ON, et al. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in esophageal cancer patients. Mol Imaging Radionucl Ther 2014; 23: 12-15.
Li Y, Lin Q, Luo Z, et al. Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy. Int J Clin Exp Med 2015; 8: 10947-10955.
Chhabra A, Ong LT, Kuk D, et al. Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. Br J Cancer 2015; 113: 1658–1665.
Schuurbiers OC, Meijer TW, Kaanders JH, et al. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18 FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol 2014; 9: 1485-1493.
Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006; 82: 391-395.
Journals System - logo
Scroll to top